AstaBio develops targeted radiotherapy by combining the alpha-emitting radioisotope 211-Astatine with proprietary Radiobody™ targeting molecules. This technology delivers precise radiation directly to tumor cells, effectively destroying them by breaking DNA strands while sparing healthy tissue. The company aims to provide more effective cancer treatment options with minimized side effects for improved patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments often damage healthy tissues alongside cancerous cells, leading to significant side effects and reduced quality of life for patients. Effective cancer therapy requires precise targeting of tumor cells to maximize efficacy while minimizing harm to surrounding healthy tissue.
Solution
This startup is developing a targeted radiotherapy approach that combines the alpha-emitting radioisotope 211-Astatine with proprietary Radiobody™ targeting molecules. This combination allows for precise delivery of radiation directly to tumor cells, disrupting their DNA and causing cell death. By selectively targeting cancer cells, this method aims to minimize damage to healthy tissues, potentially reducing side effects and improving treatment outcomes compared to traditional radiation therapies. The Radiobody™ molecules are designed to bind specifically to cancer cells, ensuring that the radiation is delivered where it is needed most.
Target Audience
The primary target audience includes cancer patients seeking more effective treatment options with fewer side effects, as well as oncologists and medical professionals looking for advanced radiotherapy solutions.
Features
- Utilizes 211-Astatine, an alpha-emitting radioisotope, for potent and localized radiation delivery.
- Employs proprietary Radiobody™ targeting molecules to selectively bind to tumor cells.
- Designed to disrupt DNA within cancer cells, leading to cell death.
- Aims to minimize damage to surrounding healthy tissues, reducing side effects.
- Multivalent single-domain antibodies enhance targeting precision.